BioNTech (BNTX) PT Raised to $62 at SVB Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks rattle investors; Broadcom gains
- Oil prices jump 7% as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
BioNTech SE (BNTX) Reports Q2 Loss of $0.38
August 11, 2020 6:05 AM EDTBioNTech SE (NASDAQ: BNTX) reported Q2 EPS of ($0.38), versus ($0.24) reported last year.
Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was 41.8 million for the three months ended June 30, 2020, compared to 25.8 million for the three months ended June 30, 2019. For the period of six months ended June 30, 2020, total revenue was 69.4 million, compared to 51.9 million for the comparative prior year period. The revenue from collaboration agreements overall increased due to the recognition of revenue from our new collaboration agreements signed with Pfizer and Fosun Pharma as part of the Companys BNT162 vaccine program against... More
